Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 4/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746284 | 0.89 | TBXAS1 (0.38) | EGLN3MAPK1SMN1; SMN2KMOTBXAS1 | |
| SCHEMBL4663218 | 0.65 | EGLN3 (0.50) | EGLN3MAPK1ESR1LMNAKMT2A | |
| SCHEMBL1712634 | 0.65 | EGLN3 (0.50) | EGLN3MAPK1ESR1KMOLMNA | |
| Hydrochloric Acid SCHEMBL17337686 | 0.64 | EGLN3 (0.48) | EGLN3MAPK1ESR1SMN1; SMN2LMNA | |
| SCHEMBL21570204 | 0.64 | EGLN3 (0.44) | EGLN3MAPK1ESR1SMN1; SMN2TBXAS1 | |
| SCHEMBL960665 | 0.64 | TBXAS1 (0.40) | MAPK1SMN1; SMN2TBXAS1MEN1LMNA | |
| SCHEMBL959796 | 0.64 | TBXAS1 (0.40) | MAPK1SMN1; SMN2TBXAS1MEN1LMNA | |
| SCHEMBL3736083 | 0.64 | EGLN3 (0.40) | EGLN3MAPK1ESR1KMOALDH1A1 | |
| SCHEMBL28396604 | 0.63 | — | — | |
| SCHEMBL6631580 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829580-B2 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695962-A1 | CYCLIC AMINE DERIVATIVE HAVING HETEROARYL RING | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | F12, F2, H1-3 | EGLN3 116/4885MAPK1 861/4885ESR1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.